Listed

Perspective Therapeutics, Inc.

CATXNYSECIK 728387HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue−$4.9m, Q4 FY2023
Operating income−$29.3m, Q2 FY2026
Net income−$26.8m, Q2 FY2026
Perspective Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m2.2Revenue, Q3 FY2023, three months to 2023-09-30$2.2m. XBRL concept us-gaap:Revenues. 10-Q filed 2023-11-14, accession 0001437749-23-032036.Report this figure(4.9)Revenue, Q4 FY2023, three months to 2023-12-31−$4.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-03-28, accession 0001437749-24-009696. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Cost of revenue$m1.4Cost of revenue, Q3 FY2023, three months to 2023-09-30$1.4m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2023-11-14, accession 0001437749-23-032036.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Gross profit$m0.7Gross profit, Q3 FY2023, three months to 2023-09-30$738.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2023-11-14, accession 0001437749-23-032036.Report this figure(0.0)Gross profit, Q4 FY2023, three months to 2023-12-31−$39.0k. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-03-28, accession 0001437749-24-009696. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m5.6Research and development, Q3 FY2023, three months to 2023-09-30$5.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0000950170-24-125399.Report this figure7.1Research and development, Q4 FY2023, three months to 2023-12-31$7.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K/A filed 2025-03-28, accession 0000950170-25-046758. Derived: 12-month figure less the 9-month figure.Report this figure7.5Research and development, Q1 FY2024, three months to 2024-03-31$7.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-12, accession 0000950170-25-069314.Report this figure9.3Research and development, Q2 FY2024, three months to 2024-06-30$9.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-13, accession 0000950170-25-107619.Report this figure12.0Research and development, Q3 FY2024, three months to 2024-09-30$12.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure12.9Research and development, Q4 FY2024, three months to 2024-12-31$12.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-16, accession 0000728387-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure14.3Research and development, Q1 FY2025, three months to 2025-03-31$14.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure16.6Research and development, Q2 FY2025, three months to 2025-06-30$16.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure20.3Research and development, Q3 FY2025, three months to 2025-09-30$20.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure32.9Research and development, Q4 FY2025, three months to 2025-12-31$32.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-16, accession 0000728387-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure21.4Research and development, Q1 FY2026, three months to 2026-03-31$21.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure21.5Research and development, Q2 FY2026, three months to 2026-06-30$21.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure
Operating income$m(9.8)Operating income, Q3 FY2023, three months to 2023-09-30−$9.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0000950170-24-125399.Report this figure(11.7)Operating income, Q4 FY2023, three months to 2023-12-31−$11.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K/A filed 2025-03-28, accession 0000950170-25-046758. Derived: 12-month figure less the 9-month figure.Report this figure(13.0)Operating income, Q1 FY2024, three months to 2024-03-31−$13.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-12, accession 0000950170-25-069314.Report this figure(14.3)Operating income, Q2 FY2024, three months to 2024-06-30−$14.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-13, accession 0000950170-25-107619.Report this figure(18.6)Operating income, Q3 FY2024, three months to 2024-09-30−$18.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure(45.0)Operating income, Q4 FY2024, three months to 2024-12-31−$45.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0000728387-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure(21.8)Operating income, Q1 FY2025, three months to 2025-03-31−$21.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure(24.0)Operating income, Q2 FY2025, three months to 2025-06-30−$24.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure(27.9)Operating income, Q3 FY2025, three months to 2025-09-30−$27.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure(39.8)Operating income, Q4 FY2025, three months to 2025-12-31−$39.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0000728387-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure(28.3)Operating income, Q1 FY2026, three months to 2026-03-31−$28.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure(29.3)Operating income, Q2 FY2026, three months to 2026-06-30−$29.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure
Interest expense$m0.0Interest expense, Q3 FY2023, three months to 2023-09-30$14.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-14, accession 0001437749-23-032036.Report this figure0.0Interest expense, Q4 FY2023, three months to 2023-12-31$24.0k. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-03-28, accession 0001437749-24-009696. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2023-11-14, accession 0001437749-23-032036.Report this figure7.8Income tax, Q4 FY2023, three months to 2023-12-31$7.8m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K/A filed 2025-03-28, accession 0000950170-25-046758. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(10.4)Net income, Q3 FY2023, three months to 2023-09-30−$10.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0000950170-24-125399.Report this figure(24.7)Net income, Q4 FY2023, three months to 2023-12-31−$24.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K/A filed 2025-03-28, accession 0000950170-25-046758. Derived: 12-month figure less the 9-month figure.Report this figure(12.3)Net income, Q1 FY2024, three months to 2024-03-31−$12.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure(11.7)Net income, Q2 FY2024, three months to 2024-06-30−$11.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure(15.1)Net income, Q3 FY2024, three months to 2024-09-30−$15.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure(40.2)Net income, Q4 FY2024, three months to 2024-12-31−$40.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0000728387-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure(18.2)Net income, Q1 FY2025, three months to 2025-03-31−$18.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure(21.5)Net income, Q2 FY2025, three months to 2025-06-30−$21.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure(26.0)Net income, Q3 FY2025, three months to 2025-09-30−$26.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure(37.5)Net income, Q4 FY2025, three months to 2025-12-31−$37.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0000728387-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure(26.2)Net income, Q1 FY2026, three months to 2026-03-31−$26.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure(26.8)Net income, Q2 FY2026, three months to 2026-06-30−$26.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure
Diluted EPS$ per share(0.37)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0000950170-24-125399.Report this figurenot reported(0.25)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-12, accession 0000950170-25-069314.Report this figure(0.18)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-13, accession 0000950170-25-107619.Report this figure(0.21)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figurenot reported(0.25)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure(0.29)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure(0.35)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figurenot reported(0.25)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure(0.22)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure
Basic EPS$ per share(0.37)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0000950170-24-125399.Report this figurenot reported(0.25)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-12, accession 0000950170-25-069314.Report this figure(0.18)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-13, accession 0000950170-25-107619.Report this figure(0.21)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figurenot reported(0.25)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure(0.29)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.29 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure(0.35)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.35 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figurenot reported(0.25)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure(0.22)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure

Balance sheet

Cash and equivalents$48.5m, Q2 FY2026
Long-term debt$1.6m, Q2 FY2026
Shareholders' equity$323.9m, Q2 FY2026
Perspective Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m18.0Cash and equivalents, Q3 FY2023, at 2023-09-30$18.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0000950170-24-125399.Report this figure9.2Cash and equivalents, FY2023, at 2023-12-31$9.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K/A filed 2025-03-28, accession 0000950170-25-046758.Report this figure142Cash and equivalents, Q1 FY2024, at 2024-03-31$142.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-12, accession 0000950170-25-069314.Report this figure252Cash and equivalents, Q2 FY2024, at 2024-06-30$252.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-13, accession 0000950170-25-107619.Report this figure226Cash and equivalents, Q3 FY2024, at 2024-09-30$226.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0000950170-24-125399.Report this figure61.6Cash and equivalents, FY2024, at 2024-12-31$61.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-16, accession 0000728387-26-000004.Report this figure44.4Cash and equivalents, Q1 FY2025, at 2025-03-31$44.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-12, accession 0000950170-25-069314.Report this figure28.8Cash and equivalents, Q2 FY2025, at 2025-06-30$28.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-13, accession 0000950170-25-107619.Report this figure26.8Cash and equivalents, Q3 FY2025, at 2025-09-30$26.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure30.6Cash and equivalents, FY2025, at 2025-12-31$30.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure54.0Cash and equivalents, Q1 FY2026, at 2026-03-31$54.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure48.5Cash and equivalents, Q2 FY2026, at 2026-06-30$48.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure
Current assets$m21.7Current assets, Q3 FY2023, at 2023-09-30$21.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-14, accession 0001437749-23-032036.Report this figure16.8Current assets, FY2023, at 2023-12-31$16.8m. XBRL concept us-gaap:AssetsCurrent. 10-K/A filed 2025-03-28, accession 0000950170-25-046758.Report this figure188Current assets, Q1 FY2024, at 2024-03-31$188.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-15, accession 0000950170-24-060427.Report this figure294Current assets, Q2 FY2024, at 2024-06-30$294.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-13, accession 0000950170-24-096148.Report this figure270Current assets, Q3 FY2024, at 2024-09-30$270.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0000950170-24-125399.Report this figure231Current assets, FY2024, at 2024-12-31$231.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-16, accession 0000728387-26-000004.Report this figure216Current assets, Q1 FY2025, at 2025-03-31$215.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-12, accession 0000950170-25-069314.Report this figure196Current assets, Q2 FY2025, at 2025-06-30$196.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-13, accession 0000950170-25-107619.Report this figure179Current assets, Q3 FY2025, at 2025-09-30$178.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure148Current assets, FY2025, at 2025-12-31$148.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure275Current assets, Q1 FY2026, at 2026-03-31$275.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure242Current assets, Q2 FY2026, at 2026-06-30$241.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure
Total assets$m111Total assets, Q3 FY2023, at 2023-09-30$110.5m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-14, accession 0001437749-23-032036.Report this figure97.9Total assets, FY2023, at 2023-12-31$97.9m. XBRL concept us-gaap:Assets. 10-K/A filed 2025-03-28, accession 0000950170-25-046758.Report this figure278Total assets, Q1 FY2024, at 2024-03-31$278.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-15, accession 0000950170-24-060427.Report this figure386Total assets, Q2 FY2024, at 2024-06-30$385.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-13, accession 0000950170-24-096148.Report this figure391Total assets, Q3 FY2024, at 2024-09-30$391.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0000950170-24-125399.Report this figure341Total assets, FY2024, at 2024-12-31$341.1m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-16, accession 0000728387-26-000004.Report this figure329Total assets, Q1 FY2025, at 2025-03-31$329.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-12, accession 0000950170-25-069314.Report this figure311Total assets, Q2 FY2025, at 2025-06-30$310.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-13, accession 0000950170-25-107619.Report this figure295Total assets, Q3 FY2025, at 2025-09-30$294.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure267Total assets, FY2025, at 2025-12-31$267.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure411Total assets, Q1 FY2026, at 2026-03-31$410.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure392Total assets, Q2 FY2026, at 2026-06-30$392.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure
Current liabilities$m8.1Current liabilities, Q3 FY2023, at 2023-09-30$8.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-14, accession 0001437749-23-032036.Report this figure15.7Current liabilities, FY2023, at 2023-12-31$15.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K/A filed 2025-03-28, accession 0000950170-25-046758.Report this figure14.5Current liabilities, Q1 FY2024, at 2024-03-31$14.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-15, accession 0000950170-24-060427.Report this figure10.6Current liabilities, Q2 FY2024, at 2024-06-30$10.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-13, accession 0000950170-24-096148.Report this figure28.1Current liabilities, Q3 FY2024, at 2024-09-30$28.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0000950170-24-125399.Report this figure18.2Current liabilities, FY2024, at 2024-12-31$18.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-16, accession 0000728387-26-000004.Report this figure12.7Current liabilities, Q1 FY2025, at 2025-03-31$12.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-12, accession 0000950170-25-069314.Report this figure13.0Current liabilities, Q2 FY2025, at 2025-06-30$13.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-13, accession 0000950170-25-107619.Report this figure20.6Current liabilities, Q3 FY2025, at 2025-09-30$20.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure28.7Current liabilities, FY2025, at 2025-12-31$28.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure31.5Current liabilities, Q1 FY2026, at 2026-03-31$31.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure36.5Current liabilities, Q2 FY2026, at 2026-06-30$36.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure
Total liabilities$m11.7Total liabilities, Q3 FY2023, at 2023-09-30$11.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-14, accession 0001437749-23-032036.Report this figure22.7Total liabilities, FY2023, at 2023-12-31$22.7m. XBRL concept us-gaap:Liabilities. 10-K/A filed 2025-03-28, accession 0000950170-25-046758.Report this figure48.4Total liabilities, Q1 FY2024, at 2024-03-31$48.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-15, accession 0000950170-24-060427.Report this figure44.9Total liabilities, Q2 FY2024, at 2024-06-30$44.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-13, accession 0000950170-24-096148.Report this figure62.7Total liabilities, Q3 FY2024, at 2024-09-30$62.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0000950170-24-125399.Report this figure50.4Total liabilities, FY2024, at 2024-12-31$50.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-16, accession 0000728387-26-000004.Report this figure44.7Total liabilities, Q1 FY2025, at 2025-03-31$44.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-12, accession 0000950170-25-069314.Report this figure45.0Total liabilities, Q2 FY2025, at 2025-06-30$45.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-13, accession 0000950170-25-107619.Report this figure52.6Total liabilities, Q3 FY2025, at 2025-09-30$52.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure59.9Total liabilities, FY2025, at 2025-12-31$59.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure63.3Total liabilities, Q1 FY2026, at 2026-03-31$63.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure68.2Total liabilities, Q2 FY2026, at 2026-06-30$68.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure
Long-term debt$m1.7Long-term debt, Q3 FY2023, at 2023-09-30$1.7m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2023-11-14, accession 0001437749-23-032036.Report this figure1.7Long-term debt, FY2023, at 2023-12-31$1.7m. XBRL concept us-gaap:LongTermDebt. 10-K filed 2024-03-28, accession 0001437749-24-009696.Report this figure1.7Long-term debt, Q1 FY2024, at 2024-03-31$1.7m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-05-15, accession 0000950170-24-060427.Report this figure1.7Long-term debt, Q2 FY2024, at 2024-06-30$1.7m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-08-13, accession 0000950170-24-096148.Report this figure1.7Long-term debt, Q3 FY2024, at 2024-09-30$1.7m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-11-12, accession 0000950170-24-125399.Report this figure1.7Long-term debt, FY2024, at 2024-12-31$1.7m. XBRL concept us-gaap:LongTermDebt. 10-K/A filed 2025-03-28, accession 0000950170-25-046758.Report this figure1.7Long-term debt, Q1 FY2025, at 2025-03-31$1.7m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-05-12, accession 0000950170-25-069314.Report this figure1.7Long-term debt, Q2 FY2025, at 2025-06-30$1.7m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-08-13, accession 0000950170-25-107619.Report this figure1.6Long-term debt, Q3 FY2025, at 2025-09-30$1.6m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure1.6Long-term debt, FY2025, at 2025-12-31$1.6m. XBRL concept us-gaap:LongTermDebt. 10-K filed 2026-03-16, accession 0000728387-26-000004.Report this figure1.6Long-term debt, Q1 FY2026, at 2026-03-31$1.6m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure1.6Long-term debt, Q2 FY2026, at 2026-06-30$1.6m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure
Shareholders' equity$m98.8Shareholders' equity, Q3 FY2023, at 2023-09-30$98.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0000950170-24-125399.Report this figure75.2Shareholders' equity, FY2023, at 2023-12-31$75.2m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-16, accession 0000728387-26-000004.Report this figure230Shareholders' equity, Q1 FY2024, at 2024-03-31$229.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure341Shareholders' equity, Q2 FY2024, at 2024-06-30$341.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure328Shareholders' equity, Q3 FY2024, at 2024-09-30$328.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure291Shareholders' equity, FY2024, at 2024-12-31$290.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure285Shareholders' equity, Q1 FY2025, at 2025-03-31$284.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure266Shareholders' equity, Q2 FY2025, at 2025-06-30$265.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure242Shareholders' equity, Q3 FY2025, at 2025-09-30$242.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure207Shareholders' equity, FY2025, at 2025-12-31$207.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure347Shareholders' equity, Q1 FY2026, at 2026-03-31$347.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure324Shareholders' equity, Q2 FY2026, at 2026-06-30$323.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure

Cash flow

Operating cash flow−$20.6m, Q2 FY2026
Capital expenditure$14.2m, Q2 FY2026
Perspective Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(10.1)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$10.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0000950170-24-125399. Derived: 9-month figure less the 6-month figure.Report this figure(9.0)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$9.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K/A filed 2025-03-28, accession 0000950170-25-046758. Derived: 12-month figure less the 9-month figure.Report this figure13.8Operating cash flow, Q1 FY2024, three months to 2024-03-31$13.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-12, accession 0000950170-25-069314.Report this figure(8.9)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$8.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-13, accession 0000950170-25-107619. Derived: 6-month figure less the 3-month figure.Report this figure3.4Operating cash flow, Q3 FY2024, three months to 2024-09-30$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001193125-25-274328. Derived: 9-month figure less the 6-month figure.Report this figure(26.6)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$26.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0000728387-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure(21.6)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$21.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure(20.0)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$20.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001193125-26-342512. Derived: 6-month figure less the 3-month figure.Report this figure(16.3)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$16.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001193125-25-274328. Derived: 9-month figure less the 6-month figure.Report this figure(24.7)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$24.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0000728387-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure(31.5)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$31.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure(20.7)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$20.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001193125-26-342512. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.2Capital expenditure, Q3 FY2023, three months to 2023-09-30$227.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-12, accession 0000950170-24-125399. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2023, three months to 2023-12-31$89.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K/A filed 2025-03-28, accession 0000950170-25-046758. Derived: 12-month figure less the 9-month figure.Report this figure9.1Capital expenditure, Q1 FY2024, three months to 2024-03-31$9.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-12, accession 0000950170-25-069314.Report this figure1.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$1.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-13, accession 0000950170-25-107619. Derived: 6-month figure less the 3-month figure.Report this figure29.7Capital expenditure, Q3 FY2024, three months to 2024-09-30$29.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001193125-25-274328. Derived: 9-month figure less the 6-month figure.Report this figure14.6Capital expenditure, Q4 FY2024, three months to 2024-12-31$14.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-16, accession 0000728387-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure4.7Capital expenditure, Q1 FY2025, three months to 2025-03-31$4.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure1.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$1.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001193125-26-342512. Derived: 6-month figure less the 3-month figure.Report this figure2.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$2.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001193125-25-274328. Derived: 9-month figure less the 6-month figure.Report this figure5.1Capital expenditure, Q4 FY2025, three months to 2025-12-31$5.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-16, accession 0000728387-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure6.9Capital expenditure, Q1 FY2026, three months to 2026-03-31$6.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure14.2Capital expenditure, Q2 FY2026, three months to 2026-06-30$14.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001193125-26-342512. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)120.65m, Q2 FY2026
Perspective Therapeutics, Inc., shares, quarterly
Line itemUnitQ1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares229Diluted shares (weighted), Q1 FY2023, three months to 2023-03-31228,591,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-15, accession 0000950170-24-060427.Report this figure28.0Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3027,999,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-13, accession 0000950170-24-096148.Report this figure28.1Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3028,055,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0000950170-24-125399.Report this figure49.5Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3149,510,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-12, accession 0000950170-25-069314.Report this figure66.6Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3066,648,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-13, accession 0000950170-25-107619.Report this figure70.6Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3070,629,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure72.4Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3172,357,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure74.2Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3074,235,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure74.3Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3074,296,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001193125-25-274328.Report this figure104Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31103,604,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001193125-26-216790.Report this figure121Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30120,651,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure

Shares outstanding: 114.15mShares outstanding, period not labelled, at 2026-08-05114,151,663 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342512.Report this figure at Aug 5, 2026, from the cover of the 10-Q filed Aug 10, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. Listed shows no prices and gives no investment advice.